ERYTECH to Present at Cowen and Company 40th Annual Health Care Conference

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chief Executive Officer, will present a corporate update at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020 in Boston, MA.

READ MORE

ERYTECH Enters Into Strategic Supply Partnership with the German Red Cross Blood Donor Service

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that it has entered into a strategic partnership with the German Red Cross Blood Donor Service Baden-Württemberg-Hessen (GRCBDS) to complement the existing alliance with the French Blood bank (EFS) for the supply of donor red blood cells to manufacture its product candidates, including eryaspase, in Europe.

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2020

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

READ MORE

ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the presentation of a Trial in Progress Poster for the ongoing Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer at the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium in San Francisco.

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2019

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2019

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

READ MORE

ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer

First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors

ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that the full results from its Phase 2b trial evaluating eryaspase in metastatic pancreatic cancer are now published online in the European Journal of Cancer.

READ MORE

ERYTECH to Present at Jefferies 2019 HealthCare Conference in London

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chief Executive Officer of ERYTECH, is scheduled to present at the Jefferies 2019 Healthcare Conference in London on November 20, 2019. The presentation starts at 4:40 p.m. GMT/11:40 a.m. EST and will be webcast.

READ MORE

ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019

Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET.

  • TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer:
    • positive safety review by independent data monitoring committee
    • opened for patient enrollment in the United States
    • first U.S. clinical sites activated
  • Princeton manufacturing facility ready for production of clinical batches
  • Cash position of €81.9 million ($89.2 million) at the end of September
READ MORE

ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on November 8, 2019

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter 2019 conference call and webcast on Friday, November 8, 2019, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2019

Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

READ MORE

ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced two important milestones for the TRYbeCA1 Phase 3 clinical trial of eryaspase in second line metastatic pancreatic cancer.

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019

Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

READ MORE

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

Conference call and webcast on Wednesday, September 18 at 2:30 pm CET/8:30 am EDT

  • TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on plan
  • Immune modulation collaboration entered into with SQZ Biotechnologies
  • Board strengthened with appointment of Dr. Jean Paul Kress as Chairman
  • Cash position of €94.5 million ($107.5 million) at the end of June
READ MORE

ERYTECH to Host Second Quarter 2019 Conference Call and Business Update

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2019 conference call and webcast on Wednesday, September 18, 2019, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2019

Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019

Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

READ MORE

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 2019

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019.

READ MORE

ERYTECH Pharma Voting Results by Resolution from Annual General Meeting Held on June 21, 2019

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2019

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

READ MORE

ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been enrolled in its Phase 2 clinical trial, named TRYbeCA2, evaluating its lead product candidate eryaspase for the treatment of first line triple negative breast cancer (TNBC).

READ MORE

ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies

ERYTECH Pharma (ERYTECH) (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells (RBCs), announced today that it has entered into an agreement with SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments in multiple therapeutic areas, to advance novel RBC-based therapeutics for immune modulation.

READ MORE

ERYTECH Announces Opening of Operations at its New Princeton, NJ GMP Manufacturing Facility

Inauguration event held last week to officially open 30,000 sq. ft GMP manufacturing facility constructed in Princeton, NJ to produce lead product candidate eryaspase in the United States.

READ MORE

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 21, 2019

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the availability of the documents for its Annual General Meeting to be held on June 21, 2019.

READ MORE

ERYTECH Announces FDA’s Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the acceptance by the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for eryaspase, consisting of the enzyme L-asparaginase encapsulated inside donor derived red blood cells. The acceptance of the IND will enable ERYTECH to initiate enrollment at US trial sites for its ongoing pivotal Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer.

READ MORE

ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provides a business update and reports its financial results for the quarter ended March 31, 2019.

READ MORE

ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, is announcing that the Board of Directors will propose the appointment of Jean-Paul Kress as a Director at the Annual General Meeting on June 21, 2019, with a view to appointing him as Chairman of the Board of Directors. Dr. Kress possesses over 25 years’ experience as a senior executive in international biotech and pharma groups.

READ MORE

ERYTECH to Host on May 7, 2019 First Quarter Conference Call and Business Update

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2019 first quarter conference call and webcast on Tuesday, May 7, 2019, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2019

READ MORE

ERYTECH Presents New Erymethionase Preclinical Findings at the 2019 AACR Annual Meeting

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced today the presentation of a poster highlighting new preclinical results for the Company’s second product candidate, erymethionase, at the 2019 American Association of Cancer Research (AACR) annual meeting held in Atlanta, Georgia. The poster (Abstract 2258) is available at www.erytech.com.

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2019

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

Listing markets:
Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

READ MORE

ERYTECH Provides Business Update and Reports Financial Results for Full Year 2018

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the year ended December 31, 2018.

READ MORE

ERYTECH Presents Findings at European Red Cell Research Society Meeting

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that an oral presentation entitled “Comprehensive proteomic profiling of erythrocytes following hypotonic dialysis-based drug encapsulation process“ will be presented today at the 22nd meeting of the European Red Cell Research Society (ERCS) in Ascona, Switzerland. A poster highlighting the results of this work will also be presented at the ERCS Meeting and will be available on the Company’s website at www.erytech.com after March 11, 2019.

READ MORE

ERYTECH to Present at Cowen & Company 39th Annual Healthcare Conference Meeting

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that Gil Beyen, the company’s chairman and chief executive officer, will present at the Cowen & Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 at The Marriott Copley Place, in Boston, MA.

Conference Details:

  • Conference: Cowen and Company 39th Annual Health Care Conference
  • Date: March 13, 2019
  • Presentation Time: 8:40am EDT / 13:40 CET
READ MORE

ERYTECH to Host Fourth Quarter and Full Year 2018 Conference Call and Business Update

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2018 conference call and webcast on Tuesday, March 12, 2019, at 1:30 PM CET/8:30 AM EST to discuss operational highlights.

READ MORE

ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled “TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)” will be presented today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in San Francisco. The poster (Abstract # TPS471) will be available at www.erytech.com after presentation at the conference.

READ MORE

ERYTECH Partners with New York Blood Center for Red Blood Cell Supply and Research

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a strategic partnership with New York Blood Center (NYBC) for red blood cell supply and research.

READ MORE

ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended September 30, 2018.

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2018

READ MORE

ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a Key Opinion Leader (KOL) breakfast symposium, focused on the potential of eryaspase to treat patients with pancreatic cancer and triple-negative breast cancer, on Wednesday, November 7, 2018 from 8:00 A.M. – 11:00 A.M. ET in New York City.

READ MORE

ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference

ERYTECH Pharma today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the Jefferies Global Healthcare on November 15th, 2017 at the Waldorf Hilton Hotel (Aldwych) in London, UK.

READ MORE

ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three patients have been enrolled in its pivotal Phase 3 clinical trial, named ‘TRYbeCA1’, evaluating its lead product candidate eryaspase for the treatment of second line metastatic pancreatic cancer.

READ MORE

ERYTECH to Attend Upcoming Investor Conferences

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that members of its management team will present and host investor meetings at the following investor conferences in September 2018.

READ MORE

ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended June 30, 2018.

READ MORE

ERYTECH to Host Second Quarter 2018 Conference Call and Bussiness Update

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a second quarter 2018 conference call and webcast on Tuesday, September 11, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.

READ MORE

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including:

READ MORE

ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications. The company also announced that it plans to cease its development program for eryaspase in acute lymphoblastic leukemia (ALL), including the withdrawal of its previously submitted MAA for eryaspase for the treatment of relapsed and refractory ALL.

READ MORE

ERYTECH to Present at JMP Securities Life Science Conference

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the JMP Securities Life Science Conference, June 20, 2018 at The St. Regis, New York, in New York City.

READ MORE

ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress, being held June 14-17, 2018 in Stockholm, Sweden.

READ MORE

General Meeting to be held on June 28, 2018 and Availability of Related Materials

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the availability of documents for its Annual General Meeting, to be held on June 28, 2018.

READ MORE

ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present pharmacodynamic characterization data from its Phase 2/3 trial of eryaspase (GRASPA®) in combination with chemotherapy for the treatment of relapsed acute lymphoblastic leukemia (ALL) at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018 in Chicago, Illinois.

READ MORE

ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018 at The Grand Hyatt, in New York City.

READ MORE

ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended March 31, 2018

READ MORE

ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice President Commercial Strategy and member of the executive team. Mr. Dusek brings 25 years of experience in market access, product marketing and sales across small biotech start-ups and multi-national pharmaceutical companies.

READ MORE

ERYTECH to Host First Quarter 2018 Conference Call and Business Update

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 first quarter conference call and webcast on Tuesday, May 15, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.

READ MORE

ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC).

READ MORE

ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018

Lyon (France), April 12, 2018 – ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present full results from its U.S. Phase I trial evaluating eryaspase (GRASPA) in combination with chemotherapy for the treatment of acute lymphoblastic leukemia (ALL) and pre-clinical data on the erymethionase program at the upcoming American Association for Cancer Research Annual Meeting, being held April 14-18, 2018 in Chicago, Illinois.

READ MORE

ERYTECH to Webcast Presentation at the Cowen and Company 38th Annual Healthcare Conference

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at The Marriott Copley Place, in Boston, MA.

READ MORE

ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the year ended December 31, 2017.

READ MORE

ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2017 conference call and webcast on Tuesday, March 13, 2018, at 1:30 PM CET/8:30 AM EST to discuss operational highlights.

READ MORE

ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase

LYON, France – February 13, 2018 – ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the selection of Triple Negative Breast Cancer as the next target indication for broadening the scope of eryaspase (GRASPA®) development in solid tumors.

READ MORE

ERYTECH to Present at the 2018 BIO CEO & Investor Conference

LYON, France – February 8, 2018 – ERYTECH Pharma (Euronext Paris: ERYP, Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chief Executive Officer, will present at the 2018 BIO CEO & Investor Conference, being held February 12-13, 2018 at the New York Marriott Marquis in New York City.

READ MORE

Monthly information related to total number of voting rights and shares composing the share capital

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

READ MORE

ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML

ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) (“ERYTECH”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced topline results from its Phase 2b clinical study evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML).

READ MORE

ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million

ERYTECH Pharma today announced the initial closing of its previously announced global offering to specified categories of investors of an aggregate of 5,374,033 new ordinary shares, comprising an offer of 4,686,106 ordinary shares in the form of American Depositary Shares, each representing one ordinary share (“ADSs”), in the United States at an offering price of $23.26 per ADS and a concurrent private placement in Europe (including France) and other countries outside of the United States and Canada of 687,927 ordinary shares at an offering price of €20.00 per ordinary share. In addition, the underwriters for the global offering have exercised in full their option to purchase at the same price 702,915 additional ADSs and 103,189 additional ordinary shares in the global offering, with the additional closing expected to occur on November 16, 2017. Following the additional closing, aggregate net proceeds to ERYTECH, after deducting underwriting commissions and estimated offering expenses payable by ERYTECH, will be approximately $130 million. All of the securities sold in the global offering were offered by ERYTECH.

READ MORE

ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference

ERYTECH Pharma today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the Jefferies Global Healthcare on November 15th, 2017 at the Waldorf Hilton Hotel (Aldwych) in London, UK.

READ MORE

ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017

ERYTECH Pharma today announced that it will host a Third Quarter 2017 conference call and webcast on Tuesday, November 14, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.

READ MORE

Erytech announces trading resumption of its ordinary shares on Euronext Paris

ERYTECH Pharma announces trading resumption of its ordinary shares on Euronext Paris as from 4:00pm CET.

READ MORE

Erytech announces trading suspension of its ordinary shares on Euronext Paris

Trading in the ordinary shares of ERYTECH Pharma, was suspended at the request of the Company on November 10, 2017 from 9:00 am CET in connection with its previously announced global offering in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company’s American Depositary Shares (“ADSs”) on the Nasdaq Global Select Market.

READ MORE

ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update

ERYTECH today provided a business update and reported its financial results for the quarter ended September 30, 2017.

READ MORE

ERYTECH Announces Launch of Proposed Global Offering and NASDAQ Listing

ERYTECH today announced its intention to issue and sell, subject to market and other conditions, approximately $125 million corresponding to an aggregate of up to 5,319,148 of its ordinary shares in a global offering to specified categories of investors, including an offer of American Depositary Shares, each representing one ordinary share (“ADSs”), in the United States and a concurrent private placement of ordinary shares in Europe (including France) and other countries outside of the United States and Canada (together, the “Global Offering”). ERYTECH intends to grant the underwriters a 30-day over-allotment option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.

READ MORE

ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia

ERYTECH today announced that it has resubmitted to the European Medicine Agency (EMA) its Marketing Authorization Application (MAA) for eryaspase (GRASPA®) for the treatment of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). The MAA resubmission includes the data from ERYTECH’s GRASPALL 2009-06 Phase 2/3 clinical trial in children and adults with R/R ALL as well as additional data to address the outstanding questions of the Committee for Medicinal Products for Human Use (CHMP) of the EMA.

READ MORE

ERYTECH Files Registration Statement for Proposed Initial Public Offering in the United States

ERYTECH today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its American Depositary Shares (“ADSs”), each representing one ordinary share, in the United States and a concurrent private placement of its ordinary shares in Europe and other countries outside of the United States and Canada (together, the “Global Offering”). All securities to be sold in the Global Offering will be offered by ERYTECH. The number of securities to be sold and the price range for the proposed Global Offering have not yet been determined. ERYTECH has applied to list its ADSs on the NASDAQ Global Market under the ticker symbol “ERYP.” The ordinary shares are listed on Euronext Paris under the symbol “ERYP.”

READ MORE

ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL

ERYTECH today announced the determination of the recommended pivotal Phase 3 dosing from its U.S. Phase 1 dose escalation study with eryaspase (GRASPA®) in first line treatment of adult ALL patients.

READ MORE

ERYTECH to Present at Morgan Stanley Global Healthcare Conference

ERYTECH today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the 15th Annual Morgan Stanley Global Healthcare Conference on September 13th, 2017 at the Grand Hyatt Hotel in New York City..

READ MORE

ERYTECH Reports First Half 2017 Financial Results and Provides Business Update

ERYTECH today provided a business update and reported its financial results for the six-month period ended June 30, 2017.

READ MORE

ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line

ERYTECH today announced the presentation of the full data from its Phase 2b study evaluating eryaspase (GRASPA®) in combination with chemotherapy for the treatment of metastatic pancreatic cancer. The open-label, multi-center, randomized Phase 2b clinical study met its co-primary endpoints and demonstrated significant improvement in both overall survival (OS) and progression-free survival (PFS). The results will be presented during the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid.

READ MORE

ERYTECH to Host Second Quarter 2017 Conference Call and Business Update

ERYTECH today announced that it will host a Second Quarter 2017 conference call and webcast on Tuesday, September 12, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.

READ MORE

ERYTECH to Present Pre-Clinical Data at the 13th International Congress of Inborn Errors of Metabolism

ERYTECH today announced that two abstracts on its preclinical erymethionase and eryminase programs were accepted for poster presentation at the 13th International Congress of Inborn Errors of Metabolism (ICIEM), being held September 5 – 8, 2017 in Rio De Janeiro, Brazil.

READ MORE

ERYTECH to Present Full Results for Phase 2b Trial of eryaspase in Pancreatic Cancer at ESMO 2017

ERYTECH today announced that it will present the full data from its Phase 2b trial evaluating eryaspase for the treatment of metastatic pancreatic cancer at the upcoming European Society for Medical Oncology Annual Meeting, being held September 8 – 12, 2017 in Madrid, Spain.

READ MORE

ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders

ERYTECH today announced that it has entered into a research collaboration with Queen’s University in Canada to advance the preclinical development of ERYTECH’s eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism. The collaboration will leverage the expertise of Queen’s University and ERYTECH’s ERYCAPS platform technology with the goal of generating in vivo proof-of-concept data in an arginase-1 deficiency animal model.

READ MORE

ERYTECH PHARMA : ANNUAL GENERAL MEETING OF JUNE 27, 2017

ERYTECH announced today the modalities for making available the documents for the Annual General Meeting of June 27, 2017.

READ MORE

ERYTECH Provides Business Update and Financial Highlights for Q1 2017

ERYTECH today provided a financial and business update for the first quarter of 2017 ended March 31, 2017.

READ MORE

Erytech to Hold Q1 2017 Business Update Conference Call on May 19th, 2017

ERYTECH today announced that it will release its financial results and business update for the quarter ended March 31, 2017 on Thursday, May 18, 2017 after the close of trading on the Euronext Paris.

READ MORE

ERYTECH TO RAISE €70.5 MILLION IN A PRIVATE PLACEMENT TO U.S. AND EUROPEAN INVESTORS

ERYTECH announces today that, in connection with the anticipated completion of a capital increase of 3,000,000 new ordinary shares reserved, it has obtained commitments from qualified investors in the United States and in Europe to purchase ordinary shares of the Company in a private placement reserved for a specified category of investors described below (the “Reserved Offering”). Total gross proceeds from the Reserved Offering placement are expected to be €70.5 million, before deducting fees and expenses. Jefferies International Limited acted as Sole Global Coordinator and acted together with Cowen and Company, LLC and Oddo & Cie as Joint Bookrunners in the Reserved Offering.

READ MORE

ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL

ERYTECH today announced the launch of an investigator-initiated study to evaluate eryaspase, also known by the trade name GRASPA®, in patients with acute lymphoblastic leukemia (ALL). The study will take place in seven Nordic countries and be conducted in collaboration with the Nordic Society of Pediatric Hematology and Oncology (NOPHO).

READ MORE

ERYTECH makes its 2016 Reference Document available

ERYTECH today announced that it had filed on March 31, 2017 with the “Autorité des Marchés Financiers (AMF)”, its 2016 Reference Document, including the management report and the annual financial report.

READ MORE

ERYTECH reports positive Phase 2b data for eryaspase for the treatment of metastatic pancreatic cancer

ERYTECH today announced positive topline results from its Phase 2b clinical study evaluating its product candidate, eryaspase (GRASPA®), in combination with chemotherapy for the treatment of second-line metastatic pancreatic cancer. The multicenter, randomized Phase 2b study met its prespecified co-primary endpoints, and showed significant improvement in both progression-free survival (PFS) and overall survival (OS) in patients treated with eryaspase combined with chemotherapy compared to chemotherapy alone.

READ MORE

ERYTECH collaborates with Fox Chase Cancer Center to advance its platform in the field of rare metabolic disorders

ERYTECH today that it has entered into a research collaboration with Fox Chase Cancer Center (FCCC) to advance the pre-clinical development of the Company’s erymethionase program for homocystinuria, a rare and severe metabolic disorder of methionine metabolism. The collaboration will leverage FCCC’s world-class expertise to generate in vivo proof-of-concept data with erymethionase in a homocystinuria animal model.

READ MORE

ERYTECH Presents New Preclinical Anti-Tumor Data on erymethionase at AACR 2017

ERYTECH today announced the presentation of new anti-tumor data supporting the Company’s preclinical product erymethionase (ERY-MET) at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 1 – 5, 2017 in Washington, D.C.

READ MORE

ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings

ERYTECH today announced the presentation of encouraging preclinical data supporting the Company’s ERYMMUNE program at two upcoming immunotherapy medical meetings, World ADOPT Summit 2017 and 10th Symposium of Vaccinology. The World ADOPT Summit 2017 is being held March 7-9, 2017 at the Cavendish Conference Centre in London, U.K., and the 10th Symposium of Vaccinology is being held March 20-21, 2017 at the Université Lumière Lyon II in Lyon, France. In conjunction with the Symposium of Vaccinology, ERYTECH will also share the results with the members of the French Society of Immunology.

READ MORE

ERYTECH Provides Business Update and Reports Financial Results for Full Year 2016

ERYTECH today provided a business update and reported its financial results for the year ended December 31, 2016.

READ MORE

ERYTECH to hold Business Update and 2016 Financial Results Conference Call on March 3rd, 2017

ERYTECH today announced that it will release its financial results and business update for the year ended December 31, 2016 on Thursday, March 02, 2017 after the close of trading on the Euronext Paris.

READ MORE

ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium

ERYTECH today announced new data supporting the second Company’s product candidate ERY-MET will be presented at the 2017 Gastrointestinal Cancers Symposium co-sponsored by the American Society of Clinical Oncology (ASCO GI), being held January 19 – 21, 2017 in San Francisco, California.

READ MORE

ERYTECH RAISES €10 MILLION IN PRIVATE PLACEMENT WITH U.S. AND EUROPEAN INVESTORS

ERYTECH today announced the closing of a private placement of 793,877 ordinary shares to qualified investors in the United States and Europe for total gross proceeds of approximately €10 million.

READ MORE

ERYTECH Presents New Data on GRASPA’s Mechanism of Action at ASH Annual Meeting

ERYTECH today announced the presentation of promising preliminary data for the Company’s lead product candidate, eryaspase, also known as ERY-ASP or under the trade name GRASPA®, at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 3-6, 2016 in San Diego, California.

READ MORE

ERYTECH Announces Withdrawal of its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission

ERYTECH today announced its decision to withdraw the current MAA for GRASPA for the treatment of acute lymphoblastic leukemia (ALL). The Company determined that the time allowed in the CHMP procedure was not sufficient to provide the additional data requested in the CHMP’s Day 180 List of Outstanding Issues (LOI). The Company intends to resubmit an MAA around mid-2017.

READ MORE

ERYTECH Provides Business Update and Reports Financial Highlights for Third Quarter 2016

ERYTECH today provided a business update and reported its financial results for the quarter ended September 30, 2016.

READ MORE

ERYTECH Strengthens Executive Leadership Team with Appointments of Chief Scientific Officer and Chief Business Officer

ERYTECH today announced the appointments of Dr. Alexander Scheer, Ph.D. as the company’s Chief Scientific Officer and Jean-Sébastien Cleiftie, as Chief Business Officer.

READ MORE

ERYTECH to Hold Q3 2016 Business Update Conference Call on November 4th, 2016

ERYTECH today announced that it will release its financial results and business update for the quarter ended September 30, 2016 on Thursday, November 03, 2016 after the close of trading on the Euronext Paris.

READ MORE

ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer

ERYTECH Pharma today announced the final patient has been enrolled in its Phase 2 trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of pancreatic cancer.

READ MORE

ERYTECH Reports Business and Financial Update for the First Half of 2016

ERYTECH Pharma today provided a business update and reported its financial results for the six month period ended June 30, 2016.

READ MORE

ERYTECH Appoints Allene M. Diaz to its Board of Directors

ERYTECH Pharma today announced the appointment of Allene M. Diaz to its Board of Directors as a nonvoting member (censeur).

READ MORE

ERYTECH to Hold Q2 2016 Business Update Conference Call on September 7th, 2016

ERYTECH Pharma today announced that it will release its financial results and business update for the quarter ended June 30, 2016 on Tuesday, September 06, 2016 after the close of trading on the Euronext Paris.

READ MORE

ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia

ERYTECH Pharma today announced that it has reached full patient enrollment in the Phase 2b trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of acute myeloid leukemia (AML).

READ MORE

ERYTECH PHARMA : ANNUAL GENERAL MEETING OF JUNE 24, 2016

Erytech announced today the modalities for making available the documents for the Annual General Meeting of June 24, 2016.

READ MORE

ERYTECH Provides Business and Financial Highlights for First Quarter 2016

Erytech today provided a business update and reported financial results for its first quarter ended March 31, 2016.

READ MORE

Erytech to Hold Q1 2016 Business Update Conference Call on May 11th, 2016

Erytech today announced that it will release its financial results and business update for the quarter ended March 31, 2016 on Tuesday, May 10, 2016 after the close of trading on the Euronext Paris.

READ MORE

ERYTECH makes its 2015 Reference Document available

ERYTECH today announced that it had filed on April 29, 2016 with the “Autorité des Marchés Financiers (AMF)”, its 2015 Reference Document, including the management report and the annual financial report.

READ MORE

ERYTECH to Present Two Posters at AACR

ERYTECH today announced that it will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 16-20, 2016 in New Orleans, LA, USA.

READ MORE

ERYTECH Receives USPTO Notice of Allowance for Patent Covering ERYCAPS Immunotherapy Technology

ERYTECH today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 12/672,094 entitled “Composition and Therapeutic Anti-tumor Vaccine.”

READ MORE

ERYTECH Provides Business Update and Reports Financial Results for Full Year 2015

Conference call and webcast on Wednesday, February 24th at 15:00 pm CET/09:00 am EST

READ MORE

Erytech to Hold Full-year 2015 Business Update Conference Call on February 24, 2016

READ MORE

Erytech Announces 2016 Financial Calendar

ERYTECH today published its financial calendar for 2016.

READ MORE

Erytech to Present at Upcoming Investor Conferences

ERYTECH will present at the 18th Annual BIO CEO and Investor Conference being held February 8-9, 2016 and the Leerink Partners 5th Annual Global Healthcare Conference being held February 10-11, 2016. Both conferences are being held at the Waldorf Astoria Hotel in New York.

READ MORE

ERYTECH Reports Financial Highlights for Q4 2015

ERYTECH reports revenue and cash balance for the fourth quarter of 2015.

READ MORE

ERYTECH Announces Third DSMB Safety Review and Continuation of Its Phase 2b Study in Acute Myeloid Leukemia

ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB1) completed its third safety assessment of the company’s Phase 2b ENFORCE 1 study in acute myeloid leukemia (AML) and that enrollment will continue until completion.

READ MORE

ERYTECH Announces Management Change

ERYTECH today announced that Yann Godfrin will be leaving the company to pursue new entrepreneurial projects.

READ MORE

ERYTECH wins the European Small and Mid-Cap Award in the Most Innovative Newcomer category

ERYTECH announced today that it received yesterday evening the “European Small and Mid-Cap” award in the “Most Innovative Newcomer” category by the Federation of European Stock Exchanges.

READ MORE

ERYTECH Announces Presentation of Additional Data at the American Society of Hematology 57th Annual Meeting

ERYTECH announces that investigators presented additional results from the pivotal Phase 2/3 clinical trial with GRASPA that add to the body of data supporting the potential benefit of GRASPA in combination with chemotherapy in the treatment of Acute Lymphoblastic Leukemia (ALL).

READ MORE

ERYTECH raises approximately €25.4 million in a private placement

ERYTECH today announces the closing of a private placement of 940,000 ordinary shares to qualified investors in the United States and Europe for a total amount of approximately €25.4 million.

READ MORE

ERYTECH to raise approximately € 25.4 million in a private placement of ordinary shares to European and U.S. institutional investors

ERYTECH today announces the pricing of a private placement of 940,000 ordinary shares to qualified investors in the United States and Europe for a total amount subscribed of approximately € 25.4 million. This private placement was conducted by Jefferies International Limited, Leerink Partners LLC and Bryan Garnier & Co. Limited, acting as placement agents and LifeSci Capital LLC, acting as co-manager.

READ MORE

ERYTECH wins Deloitte Technology Fast 50 “Promising Biotech Award” for France’s Grand Rhone-Alpes Region

ERYTECH announced today that it received Deloitte Technology Fast 50 award in the “Promising Biotech” category for France’s Grand Rhone-Alpes region.

READ MORE

ERYTECH announces data presentations at the American Society of Hematology 57th Annual Meeting

ERYTECH announces the upcoming presentation of three abstracts at the American Society of Hematology (ASH) Annual Meeting taking place in Orlando, Florida, USA from December 5-8, 2015.

READ MORE

ERYTECH reports financial highlights for Q3 2015

ERYTECH reports cash balance and revenues for the third quarter of 2015.

READ MORE

ERYTECH announces publication of two articles describing clinical results with eryaspase/GRASPA

ERYTECH announces the publication of two peer-reviewed manuscripts describing clinical results obtained with eryaspase/GRASPA®.

READ MORE

ERYTECH provides business update and financial results for the first half of 2015

ERYTECH provides a business update and reports its financial results for the six-month period ending June 30, 2015.

READ MORE

ERYTECH strengthens its intellectual property position with the issuance of United States patent for erythrocytes containing arginine deiminase

ERYTECH announces the issuance of a new patent in the United States.

ERYTECH to host a webcast on September 29, 2015 for its 2015 half-year results

ERYTECH will announce its half-year results for 2015 on Monday September 28, 2015, after market close, and hold a presentation webcast on the September 29, 2015 at 2:30 pm CET / 8:30 am EDT.

READ MORE

ERYTECH submits EMA Marketing Authorization Application for GRASPA to treat acute lymphoblastic leukemia

ERYTECH announces today the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for eryaspase (Invented Name: GRASPA®) for the treatment of patients with acute lymphoblastic leukemia (ALL).

READ MORE

ERYTECH appoints Eric Soyer as Chief Financial and Chief Operating Officer

ERYTECH announces the appointment of Eric Soyer as Chief Financial and Chief Operating Officer (CFO/COO).

READ MORE

ERYTECH announces plans to conduct registered initial public offering in the United States

ERYTECH today announced that the Company plans to conduct a registered initial public offering in the United States.

READ MORE

ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer

ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.

READ MORE

ERYTECH appoints Dr. Iman El-Hariry as Chief Medical Officer

ERYTECH announces the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs.

READ MORE

ERYTECH reports financial highlights for Q2 2015

ERYTECH reports cash balance and revenues for the second quarter of 2015.

READ MORE

ERYTECH announces two positive DSMB reviews

ERYTECH announces positive safety reviews after the completion of the first cohort in the company’s US Phase I study with eryaspase in Acute Lymphoblastic Leukemia (ALL), and following the treatment of the first three patients with eryaspase in combination with Folfox in its Phase II study in pancreatic cancer.

READ MORE

ERYTECH announces presentation and webcast at the Jefferies 2015 Healthcare Conference

ERYTECH announces that Gil Beyen, Chairman & CEO of the company, will present a company overview at the Jefferies 2015 HealthCare Conference in New York on June 4 at 9:00 am Eastern Time.

READ MORE

ERYTECH reported full GRASPA® Phase III results in ALL and provided update on AML Phase IIb at ASCO

ERYTECH reported complete Phase III results of its pivotal program with GRASPA® in Acute Lymphoblastic Leukemia (ALL) and presented the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). During an investigator meeting ERYTECH also presented the progress and plans on other development programs.

READ MORE

ERYTECH announces oral presentations of GRASPA® Phase III results at ASCO and EHA annual meetings

ERYTECH announces that the data related to GRASPA® Phase 3 pivotal program in Acute Lymphoblastic Leukemia (ALL) will be the subject of oral presentations at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2, Chicago, USA, and at the 20th Congress of European Hematology, June 11 – 14, Vienna, Austria. A poster on the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) will also be presented at ASCO.

READ MORE

ERYTECH reports financial highlights for Q1 2015

ERYTECH reports cash balance and revenues for the first quarter of 2015.

READ MORE

ERYTECH announces positive DSMB annual review of its Expanded Access Program in ALL

ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company’s Expanded Access Program (EAP) in Acute Lymphoblastic Leukemia (ALL) and recommended continuation of the program without modification.

READ MORE

ERYTECH receives the EnterNext Tech 40 Label

ERYTECH has received the EnterNext Tech 40 Label and announces its inclusion in the Tech 40 index.

READ MORE

ERYTECH strengthens its intellectual property position in the US

ERYTECH announces the strengthening of its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent.

READ MORE

ERYTECH provides business update and financial results for the full year 2014

ERYTECH provides a business update and reports its financial results for the period ending December 31, 2014.

READ MORE

ERYTECH appoints new independent board member

ERYTECH announces it has coopted Luc Dochez as new independent board member and will propose his appointment at the upcoming general assembly in June.

READ MORE

ERYTECH announces three data presentations at the 2015 AACR Annual Meeting

ERYTECH announces the upcoming presentation of three abstracts, at the American Association for Cancer Research (AACR) taking place in Philadelphia, PA, USA from 18 to 22 April 2015.

READ MORE

ERYTECH reports financial highlights for Q4 2014 and updates on upcoming milestones

ERYTECH reports revenues and cash balance for the fourth quarter of 2014 and provides an update on upcoming milestones.

READ MORE

ERYTECH announces its financial calendar for 2015

READ MORE

ERYTECH announces ADR Level 1 listing in the US

ERYTECH today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company’s US investor base.

READ MORE

ERYTECH announces management change

ERYTECH today announced that Pierre-Olivier Goineau will be leaving the company to pursue other interests.

READ MORE

ERYTECH reports additional positive Phase III results from clinical study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia

ERYTECH reports additional positive Phase III results from the pivotal study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia.

READ MORE

ERYTECH to present at Jefferies Global Healthcare Conference

ERYTECH will be presenting at Jefferies Global Healthcare Conference in London next week.

READ MORE

ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH

ERYTECH announces the presentation of four case studies with GRASPA® in an expanded access program at the 56th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2014, in San Francisco, CA.

READ MORE

ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments

ERYTECH announces today the successful completion of a capital increase for a total amount of €30 million.

READ MORE

ERYTECH announces granting of new patent in the United States

ERYTECH announces the granting of a new patent in the field of asparaginase in the United States.

READ MORE

ERYTECH wins EuropaBio’s Most Innovative European Biotech SME Award 2014

ERYTECH won EuropaBio’s Most Innovative European Biotech SME Award 2014.

READ MORE

ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia

ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia.

READ MORE

ERYTECH business update and financial results for the first half of 2014

ERYTECH provides a business update and reports its financial results for the period ending June 30, 2014.

READ MORE

ERYTECH announces second positive DSMB review of its Phase IIb study in Acute Myeloid Leukemia

ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB) completed its second safety assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) and unanimously recommended continuation of the trial without modification.

READ MORE

ERYTECH announces enrollment of first patient in Phase II study of eryaspase in pancreatic cancer

ERYTECH announces the enrollment of the first patient in its Phase II study with eryaspase in second line treatment of patients affected by pancreatic cancer.

READ MORE

ERYTECH announces enrollment of first patient in Phase I/II study of eryaspase in Acute Lymphoblastic Leukemia in the United States

ERYTECH announces the enrollment of the first patient in its Phase I/II study with eryaspase in Acute Lymphoblastic Leukemia in the United States of America.

READ MORE

ERYTECH provides financial update for Q2 2014

ERYTECH provides a financial update for the second quarter of 2014.

READ MORE

ERYTECH appoints two new independent board members

ERYTECH announces it has appointed Dr Martine George and Mrs Hilde Windels as new independent members to its board of directors.

READ MORE

ERYTECH strengthens its intellectual property portfolio

ERYTECH announces the granting of two key patents for its core product eryaspase.

READ MORE

ERYTECH provides financial update for Q1 2014

ERYTECH provides a financial update for the first quarter of 2014.

READ MORE

ERYTECH receives authorization to start its Phase II clinical study in pancreatic cancer

ERYTECH announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer.

READ MORE

ERYTECH provides business update and financial results for the full year 2013

ERYTECH provides a business update and reports its financial results for the period ending December 31, 2013.

READ MORE

ERYTECH adds a new product candidate to its Cancer Metabolism development portfolio

ERYTECH announces the addition of a new product development candidate, erymethionase, to the company’s Cancer Metabolism product pipeline.

ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia

ERYTECH announces that its lead product GRASPA®/eryasp1 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.

READ MORE

ERYTECH welcomes new US and European investors

ERYTECH was informed today that certain of its historical institutional investors have sold part of their holdings to new specialized life sciences investors in the United States and in Europe.

READ MORE

ERYTECH PHARMA launches a subscription of BSPCE warrants reserved for its main executives

ERYTECH launch a subscription of BSPCE reserved for its main executives.

READ MORE

ERYTECH gives feedback on its first Investor R&D Day and provides a financial and business update for Q4 2013

ERYTECH held its first Investor R&D day and provides a financial and business update for the fourth quarter of 2013.

READ MORE

ERYTECH announces its financial calendar for 2014

ERYTECH announces its financial calendar for 2014

READ MORE

ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML

ERYTECH announces it received authorizations for its Phase IIb GRASPA-ML clinical trial in Acute Myeloid Leukemia (AML) in Finland and Spain.

READ MORE

ERYTECH positions its lead product in solid tumors and launches a Phase II clinical study in pancreatic cancer

ERYTECH provides an update on its development plans to broaden the scope of its lead product eryaspase into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

READ MORE

ERYTECH announces the decision of USPTO to extend the additional exclusivity period of its core process patent to almost 4 years

ERYTECH announces its received final notification of allowance for the granting of its core process patent in the United States in which the term of exclusivity has been further extended from two to almost four years

READ MORE

ERYTECH announces two presentations at 55th ASH annual meeting and exposition in New Orleans

ERYTECH announces that data related to the Company’s lead product GRASPA® will be the subject of two poster presentations at the 55th American Society of Hematology (ASH) Annual Meeting and Exhibition on December 7 and 8 in New Orleans, USA.

READ MORE

ERYTECH announces positive DSMB review of its Phase IIb study in Acute Myeloid Leukemia

ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB) completed its first assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) study and unanimously recommended continuation of the trial without modification.

READ MORE

ERYTECH provides financial update for Q3 2013

ERYTECH announces today its cash position and its revenues for the third quarter of 2013.

READ MORE

ERYTECH announces the granting of its core process patent in the United States with two additional years of exclusivity

ERYTECH announces it received notification of allowance for the granting of its core process patent in the United States with two additional years of exclusivity in the United States.

READ MORE

ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia

ERYTECH announces the completion of the enrollment of patients in its pivotal Phase III study in Acute Lymphoblastic Leukemia (ALL).

READ MORE

ERYTECH business update and financial results for the first half of 2013

ERYTECH provides a business update and reports its financial results for the period ending June 30, 2013.

READ MORE

ERYTECH provides financial update for Q2 2013

ERYTECH announced today its cash position and its revenues for the second quarter of 2013.

READ MORE

ERYTECH announces fast take-off of its Phase IIb study in Acute Myeloid Leukemia

ERYTECH announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia (AML).

READ MORE

ERYTECH provides financial update for Q1 2013

ERYTECH announced today its cash position and its revenues for first quarter 2013.

READ MORE

ERYTECH to present at upcoming investor conferences

ERYTECH announced today that in May and June the company will present at several visible investor events in Europe and the U.S following its successful IPO on April, 2013. As a public company ERYTECH is committed to actively engage with investors and the financial community.

READ MORE

ERYTECH’s IPO a remarkable success, raising €17.7 million

ERYTECH today announced the success of its IPO in compartment C of the NYSE Euronext regulated market in Paris, raising more than the target amount of €15 million.

READ MORE

ERYTECH announces its IPO on NYSE Euronext Paris regulated market

ERYTECH today announces that the French market regulator Autorité des Marchés Financiers (AMF) granted its visa n°13-166 on April 17, 2013 for the prospectus relative to the listing of ERYTECH shares on the NYSE Euronext regulated market in Paris.

READ MORE

ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S.

ERYTECH announced today that it has received clearance of its Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its product ERYASP®, L-asparaginase loaded erythrocytes, in patients 40 years or older with newly diagnosed Acute Lymphoblastic Leukemia (ALL).

READ MORE

ERYTECH Pharma signs licensing and distribution agreement with Orphan Europe for GRASPA® in Europe

Erytech Pharma announced today that it has entered into a definitive agreement and Orphan Europe, part of the Recordati Group, granting Orphan Europe exclusive rights for the commercialization and distribution of GRASPA® in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) in Europe.

READ MORE

ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes.

READ MORE

ERYTECH Pharma announces the oral presentation of positive Phase II clinical trial results in Acute Lymphoblastic Leukemia.

READ MORE

ERYTECH Pharma’s sickle cell treatment receives positive opinion for Orphan Drug Designation from the European Medicines Agency

Erytech Pharma announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) adopted a positive opinion to grant Orphan Drug Designation (ODD) to its investigational product ENHOXY® for sickle cell disease.

READ MORE

ERYTECH PHARMA receives € 7 Million from OSEO to lead the TEDAC personalized medicine project in cancer

ERYTECH Pharma is pleased to announce that it received a total of € 6.95 million in support from the Strategic Industrial Innovation program of the French public organization OSEO to lead the TEDAC project (Therapeutic Enzymes to Deplete Amino acids to treat Cancers resistant to radio/chemotherapy).

READ MORE

ERYTECH Pharma completes the enrollment of patients in its Phase I clinical trial in pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®.

READ MORE

ERYTECH Pharma to partner with Teva for long term distribution agreement in Israel

ERYTECH Pharma is pleased to announce it has signed an exclusive long term agreement with Teva for the registration, marketing, distribution and sale of Graspa®, the company‟s lead product, in Israel.

READ MORE

ERYTECH Pharma to present promising results for the treatment of Sickle Cell Disease

ERYTECH Pharma will in the near future present their promising results obtained with the GR-ARA1 project for the treatment of sickle cell disease.

READ MORE

ERYTECH Pharma announces appointment of Marc Beer to the Supervisory Board

ERYTECH Pharma is pleased to welcome Marc Beer as a new board member.

READ MORE

Menu